Gene regulation by microRNAs (miRNAs) is one of the most important regulatory
networks which control normal hematopoiesis. Disturbances in miRNAs levels lead to
proliferation diseases including leukemogenesis. MicroRNAs is a major topic of many
ca
ncer researches performed to discover noninvasive biomarkers used for diagnosis,
prognosis, and optimization of clinical decision.
This study, the first to be performed in Syria, aimed at monitoring miR-155 levels
compared to a normalizer gene RNU6-2 by quantitative reverse transcriptase -PCR (qRTPCR)
in a sample of newly diagnosed untreated AML patients at several hospitals in
Damascus in comparison with healthy controls. Changes in miR-155 gene expression
levels were calculated in patients and controls using the 2-ΔCt method.
The most important finding was the association of low and very high miR-155 levels
with poor prognosis reflected in failure to accomplish complete remission and high
mortality. In addition, high miR-155 levels were associated with M4 AML subtype,
although with large variance among patients. We hope our preliminary study pave the road
for many future research studies related to the applicability of microRNAs in supporting
diagnosis, predicting prognosis, and enhancing the personalized therapies which deal with
patients as individual cases.
The goal of this research is to study the expression of epidermal and
transforming growth factor receptor in normal human bone marrow (BM)
cell, and in leukemia ( myeloid and lymphatic leukemia ) which promoted
the research for the function of EGF
R receptors in the development and
growth of BM cells and for malignancies expressing of the EGFR as
potential therapeutic targets in blood cell malignant diseases.